Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Medical Cannabis Market

ID: MRFR/MED/11321-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Medical Cannabis Market Research Report: Size, Share, Trend Analysis By Product Type (Solids, Dissolvable/ Powders, Oil, Ointments & Creams), By Derivative (Cannabidiol, Tetrahydrocannabinol), By Route of Administration (Inhalation, Oral, Topical), By Applications (Pain Management, Neurological Health Management, Mental Health Management), By Pain Management Sub-segments (Neuropathic Pain, Cancer, Inflammatory Pain) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Medical Cannabis Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Application (USD Million)
  49.     4.1.1 Pain Management
  50.     4.1.2 Neurological Disorders
  51.     4.1.3 Cancer Treatment
  52.     4.1.4 Mental Health Disorders
  53.     4.1.5 Inflammatory Conditions
  54.   4.2 Construction, BY Product Type (USD Million)
  55.     4.2.1 Flower
  56.     4.2.2 Oils
  57.     4.2.3 Tinctures
  58.     4.2.4 Edibles
  59.     4.2.5 Topicals
  60.   4.3 Construction, BY Distribution Channel (USD Million)
  61.     4.3.1 Pharmacies
  62.     4.3.2 Online Stores
  63.     4.3.3 Dispensaries
  64.   4.4 Construction, BY Formulation (USD Million)
  65.     4.4.1 Cannabinoid-Based
  66.     4.4.2 Herbal-Based
  67.     4.4.3 Synthetic
  68. 5 SECTION V: COMPETITIVE ANALYSIS
  69.   5.1 Competitive Landscape
  70.     5.1.1 Overview
  71.     5.1.2 Competitive Analysis
  72.     5.1.3 Market share Analysis
  73.     5.1.4 Major Growth Strategy in the Construction
  74.     5.1.5 Competitive Benchmarking
  75.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  76.     5.1.7 Key developments and growth strategies
  77.       5.1.7.1 New Product Launch/Service Deployment
  78.       5.1.7.2 Merger & Acquisitions
  79.       5.1.7.3 Joint Ventures
  80.     5.1.8 Major Players Financial Matrix
  81.       5.1.8.1 Sales and Operating Income
  82.       5.1.8.2 Major Players R&D Expenditure. 2023
  83.   5.2 Company Profiles
  84.     5.2.1 Canopy Growth Corporation (CA)
  85.       5.2.1.1 Financial Overview
  86.       5.2.1.2 Products Offered
  87.       5.2.1.3 Key Developments
  88.       5.2.1.4 SWOT Analysis
  89.       5.2.1.5 Key Strategies
  90.     5.2.2 Aurora Cannabis Inc. (CA)
  91.       5.2.2.1 Financial Overview
  92.       5.2.2.2 Products Offered
  93.       5.2.2.3 Key Developments
  94.       5.2.2.4 SWOT Analysis
  95.       5.2.2.5 Key Strategies
  96.     5.2.3 Tilray Brands, Inc. (CA)
  97.       5.2.3.1 Financial Overview
  98.       5.2.3.2 Products Offered
  99.       5.2.3.3 Key Developments
  100.       5.2.3.4 SWOT Analysis
  101.       5.2.3.5 Key Strategies
  102.     5.2.4 Cronos Group Inc. (CA)
  103.       5.2.4.1 Financial Overview
  104.       5.2.4.2 Products Offered
  105.       5.2.4.3 Key Developments
  106.       5.2.4.4 SWOT Analysis
  107.       5.2.4.5 Key Strategies
  108.     5.2.5 Green Thumb Industries Inc. (US)
  109.       5.2.5.1 Financial Overview
  110.       5.2.5.2 Products Offered
  111.       5.2.5.3 Key Developments
  112.       5.2.5.4 SWOT Analysis
  113.       5.2.5.5 Key Strategies
  114.     5.2.6 Curaleaf Holdings, Inc. (US)
  115.       5.2.6.1 Financial Overview
  116.       5.2.6.2 Products Offered
  117.       5.2.6.3 Key Developments
  118.       5.2.6.4 SWOT Analysis
  119.       5.2.6.5 Key Strategies
  120.     5.2.7 Trulieve Cannabis Corp. (US)
  121.       5.2.7.1 Financial Overview
  122.       5.2.7.2 Products Offered
  123.       5.2.7.3 Key Developments
  124.       5.2.7.4 SWOT Analysis
  125.       5.2.7.5 Key Strategies
  126.     5.2.8 Harvest Health & Recreation Inc. (US)
  127.       5.2.8.1 Financial Overview
  128.       5.2.8.2 Products Offered
  129.       5.2.8.3 Key Developments
  130.       5.2.8.4 SWOT Analysis
  131.       5.2.8.5 Key Strategies
  132.   5.3 Appendix
  133.     5.3.1 References
  134.     5.3.2 Related Reports
  135. 6 LIST OF FIGURES
  136.   6.1 MARKET SYNOPSIS
  137.   6.2 US MARKET ANALYSIS BY APPLICATION
  138.   6.3 US MARKET ANALYSIS BY PRODUCT TYPE
  139.   6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  140.   6.5 US MARKET ANALYSIS BY FORMULATION
  141.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  142.   6.7 RESEARCH PROCESS OF MRFR
  143.   6.8 DRO ANALYSIS OF CONSTRUCTION
  144.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  145.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  146.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  147.   6.12 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
  148.   6.13 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
  149.   6.14 CONSTRUCTION, BY PRODUCT TYPE, 2024 (% SHARE)
  150.   6.15 CONSTRUCTION, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
  151.   6.16 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  152.   6.17 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  153.   6.18 CONSTRUCTION, BY FORMULATION, 2024 (% SHARE)
  154.   6.19 CONSTRUCTION, BY FORMULATION, 2024 TO 2035 (USD Million)
  155.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  156. 7 LIST OF TABLES
  157.   7.1 LIST OF ASSUMPTIONS
  158.     7.1.1
  159.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  160.     7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  161.     7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Million)
  162.     7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  163.     7.2.4 BY FORMULATION, 2025-2035 (USD Million)
  164.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  165.     7.3.1
  166.   7.4 ACQUISITION/PARTNERSHIP
  167.     7.4.1

US Construction Market Segmentation

Construction By Application (USD Million, 2025-2035)

  • Pain Management
  • Neurological Disorders
  • Cancer Treatment
  • Mental Health Disorders
  • Inflammatory Conditions

Construction By Product Type (USD Million, 2025-2035)

  • Flower
  • Oils
  • Tinctures
  • Edibles
  • Topicals

Construction By Distribution Channel (USD Million, 2025-2035)

  • Pharmacies
  • Online Stores
  • Dispensaries

Construction By Formulation (USD Million, 2025-2035)

  • Cannabinoid-Based
  • Herbal-Based
  • Synthetic

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions